Clinical Trials Browser

Colorectal Neoplasms

NCT06901531 2026-03-11

LUCERNA

Phase 3 Recruiting

500 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT05239741 2026-03-10

MK-3475-C66

Phase 3 Recruiting

100 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06764875 2026-03-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

840 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT04230187 2026-03-05

TRIBE-C

Phase 3 Recruiting

528 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05677490 2026-03-04

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Phase 3 Recruiting

382 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06951503 2026-03-04

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Phase 3 Recruiting

560 enrolled

Gastrointestinal

Colorectal Adenocarcinoma

NCT04215731 2026-03-03

FOBEAR

Phase 3 Recruiting

582 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06508658 2026-03-03

EPCORE DLBCL-4

Phase 3 Recruiting

360 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07228832 2026-03-03

HARMONi-GI3

Phase 3 Recruiting

600 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05863195 2026-03-02

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3 Recruiting

408 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Phase 3 Recruiting

550 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07431281 2026-02-24

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

2,130 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Phase 3 Recruiting

550 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06958328 2026-02-02

LAP100

Phase 3 Recruiting

356 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Phase 3 Recruiting

387 enrolled

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT07265674 2026-01-23

Beacon-BTC

Phase 3 Recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Recruiting

555 enrolled

Gastrointestinal

Stomach Neoplasms

NCT03801876 2026-01-14

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Phase 3 Recruiting

300 enrolled

Gastrointestinal

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT06205485 2026-01-13

NEO-RT

Phase 3 Recruiting

250 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05008809 2025-12-12

AIO-KRK-0418

Phase 3 Recruiting

507 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06733038 2025-12-08

AtezoTRIBE2

Phase 3 Recruiting

238 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06929624 2025-11-18

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

280 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06490536 2025-08-29

The Sagittarius Trial

Phase 3 Recruiting

700 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

269 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02885753 2025-07-09

OSCAR

Phase 3 Recruiting

348 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT06507371 2025-06-26

mRCAT-III

Phase 3 Recruiting

170 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04861558 2025-05-30

EFFIPEC

Phase 3 Recruiting

213 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05624138 2025-05-11

The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy

Phase 3 Recruiting

64 enrolled

Neuritis

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Phase 3 Recruiting

480 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT04460352 2025-03-06

NEEDS

Phase 3 Recruiting

1,020 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Recruiting

416 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04447352 2024-11-12

PREVENT

Phase 3 Recruiting

200 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04927780 2024-08-28

PREOPANC-3

Phase 3 Recruiting

378 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05954078 2024-05-20

Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

Phase 3 Recruiting

340 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05751850 2024-05-09

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Phase 3 Recruiting

778 enrolled

Gastrointestinal

First-line Treatment of Advanced Pancreatic Cancer

NCT01935778 2024-02-28

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

Phase 3 Recruiting

286 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06201065 2024-01-11

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Phase 3 Recruiting

200 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05264896 2023-09-07

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

Phase 3 Recruiting

110 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05236972 2022-12-30

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Phase 3 Recruiting

323 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05201430 2022-03-04

RCNAC

Phase 3 Recruiting

300 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04787354 2022-02-21

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

Phase 3 Recruiting

976 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04595864 2021-11-05

Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation

Phase 3 Recruiting

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04997837 2021-08-10

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Phase 3 Recruiting

433 enrolled

Gastrointestinal

Stomach Neoplasms

Clinical Trials

MOUNTAINEER-03

LUCERNA

MK-3475-C66

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

TRIBE-C

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

FOBEAR

EPCORE DLBCL-4

HARMONi-GI3

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

LAP100

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Beacon-BTC

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

NEO-RT

AIO-KRK-0418

AtezoTRIBE2

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

The Sagittarius Trial

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

OSCAR

mRCAT-III

EFFIPEC

The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

NEEDS

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PREVENT

PREOPANC-3

Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

RCNAC

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma